Stay updated on Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.

Latest updates to the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page
- Check6 days agoChange DetectedLocation name updated from Padua to Padova for the Veneto, Italy site (35128).SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedRevision label updated to v3.5.0 with the v3.4.3 label removed.SummaryDifference0.0%

- Check35 days agoChange DetectedRevision labels updated: v3.4.3 added and v3.4.2 removed.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision: v3.4.2 was added to the site, and the previous funding-status notice (v3.4.1) was removed.SummaryDifference0.4%

- Check70 days agoChange DetectedNew site-wide notice about lapse in government funding and NIH Clinical Center operations is now visible, and the page revision has been updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check78 days agoChange DetectedAdded a glossary toggle and updated page metadata labels (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act data') with a revision bump from v3.3.4 to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.